Tarapur Transformers Ltd. Share Price

Bhageria Industries Ltd Company Analysis

Bhageria Industries is a diversified business with its core operations in specialty chemicals, particularly dye and pigment intermediates, alongside solar power generation and a developing pharmaceutical business. The chemicals segment is currently the main earnings driver, supported by expanded H-Acid capacity from 400 to 500 tonnes per month and the commencement of plasticizer production at Tarapur. FY26 showed a substantial improvement, with consolidated revenue from operations reaching about ₹874 crore versus ₹597 crore in FY25. Chemical-segment revenue increased to about ₹830 crore from ₹504 crore, while the solar segment remained relatively stable at ₹26.9 crore. Q1 FY27 continued this momentum, with consolidated revenue of ₹286.4 crore, up 81.9% YoY, and PAT of ₹33.9 crore, up 210.7%. EBITDA increased to ₹57.6 crore, with operating margin improving sharply to 20.1% from 15.4% in Q1 FY26. The major growth opportunity lies in scaling H-Acid and plasticizer capacity, improving export volumes and expanding the solar portfolio. The company commissioned additional solar capacity during FY26 and added another 7 MW in May 2026, taking installed solar capacity to 21 MW. At around ₹352 as of 24 September 2026, the stock was valued at approximately ₹1,528 crore market capitalisation, with P/E around 22.6x, ROE 7.7% and debt-to-equity around 0.17x. Key risks include specialty-chemical cyclicality, raw-material and export-market volatility, relatively modest return ratios, working-capital requirements and execution risk in new capacity. The recent earnings acceleration is significant, but sustaining margins and converting capacity expansion into consistent cash generation will be important to monitor.

See More

Aarti Drugs: Moving up the pharma value chain

# Aarti Drugs: Moving up the pharma value chain Aarti Drugs Limited is moving beyond its traditional API business through backward integration, formulations and CDMO opportunities. The company plans ₹150–200 crore of annual capex for the next two years. The key focus is metformin. Aarti Drugs has already increased capacity to around 1,450–1,500 tonnes per month and plans to take this to 1,800–1,900 tonnes. It is also pursuing US FDA approval and plans to forward-integrate into metformin formulations. The company is also exploring CDMO opportunities in chlorosulfonation chemistry, where it already has manufacturing expertise, while expanding cardiovascular and antifungal products. This matters because APIs are more exposed to pricing cycles. Moving further downstream into regulated formulations and specialised manufacturing can potentially improve realisations and margins. Aarti Drugs has already completed around ₹600 crore of capex across Sayakha and Tarapur, while management estimates more than ₹1,200 crore of revenue potential from completed projects. **My view:** The interesting part of Aarti Drugs is the transition from an API-led business toward a more integrated pharma platform. The key test is whether the new capacity gets utilised fast enough to generate attractive returns on the capital invested. **What I'm watching:** Sayakha utilisation, metformin forward integration, regulated-market approvals, CDMO wins and return on capital. **Stance:** Capacity creation is only the first step. Execution and utilisation will determine whether the investment cycle translates into sustainable earnings growth. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

See More

Vipul Organics Starts Production at Sayakha Greenfield Plant; Consolidates Pigment Ops

Vipul Organics has commenced production at its new greenfield manufacturing facility in Sayakha, Gujarat. The company has also consolidated its pigment production from the Tarapur unit at the new Sayakha plant. This expansion significantly boosts capacity and is expected to improve operational efficiencies and cost competitiveness in the pigments segment. The facility supports the company’s growth plans in specialty chemicals and high-performance pigments. Top stocks in the dyes & pigments industry: Sudarshan Chemical Industries,

, and Bodal Chemicals.

See More

Unimech Aerospace Latest Updates

Operational Recovery and Order Book Unimech Aerospace witnessed a gradual improvement in its operating environment during Q4 FY26, following a challenging first nine months marked by subdued global demand. As of March 31, 2026, the company maintains a robust order book of ₹214 crore, providing strong revenue visibility for the upcoming fiscal year. Customer procurement activity has reportedly normalized following recent adjustments in international trade and tariff policies, particularly in the US market. Major Order Wins and Expansion In early 2026, the company's subsidiary, Innomech Aerospace Toolings, secured a significant order worth ₹72.20 crore from the Nuclear Power Corporation of India (NPCIL) for support equipment at the Tarapur Atomic Power Station. Additionally, the company bagged an export order worth ₹35 crore for ground support equipment. To support this growth, Unimech recently expanded its Bengaluru manufacturing facility by 62,000 sq. ft. Strategic Partnerships and Acquisitions The company has aggressively pursued international expansion, recently receiving board approval to enter a joint venture with Saudi Arabia’s Yusuf Bin Ahmed Kanoo Company (YBAK) to establish a manufacturing presence in the Kingdom. Furthermore, in late April 2026, Unimech initiated the acquisition of a 24% stake in Hobel Bellows Private Limited, a move aimed at diversifying its high-precision engineering portfolio. Financial Performance and Stock Action For Q4 FY26, the company is expected to report revenue in the range of ₹160 to ₹178 crore, with sequential growth over Q3. This follows a period of volatility where the stock touched a 52-week low of ₹695 in March 2026 before recovering toward the ₹1,050 level by late April. The company also recently managed a transition in its secretarial leadership following the resignation of its Company Secretary in February 2026.

See More

Ipca Laboratories Latest Updates

Stock Hits 52-Week HighIpca Labs' stock reached a new 52-week high of ₹1,624 on March 17, 2026. This rally was supported by high trading volumes and follows a period of consistent financial performance, with the stock gaining approximately 18% over the past year. As of today, the stock is trading around ₹1,562, maintaining its position above major moving averages (50-day and 200-day SMAs). Manufacturing and Regulatory Updates The company recently achieved a major operational milestone with the commencement of commercial production at its new manufacturing unit in Village Hingani, Wardha district, on February 9, 2026. On the regulatory front, the USFDA completed an inspection of the Tarapur API facility in December 2025, issuing a Form 483 with three observations. The company has stated it is working closely with the regulator to resolve these issues, which is critical for its plans to ramp up its U.S. generics business. Strategic Therapy Expansion Ipca is actively restructuring its domestic portfolio to move beyond its traditional strength in pain management (the Zerodol franchise). The company is now focusing on high-growth segments such as cardiology, central nervous system (CNS), and high-end cosmo-dermatology. In Q3, while the anti-malarial segment faced a drag (down 21%), these newer therapy areas saw robust growth, with the dermatology and CNS segments growing by 22% and 19% respectively. Unichem Integration and U.S. OutlookThe integration of Unichem Laboratories is progressing, with a focus on utilizing Unichem's underused manufacturing capacity to improve overall export margins. Ipca currently has roughly 35 U.S. registrations and plans to commercialize an additional 5–7 molecules over the next 12–15 months. Management expects the U.S. business to see a more meaningful revival starting in FY27 as more products are relaunched following recent regulatory clearances.

See More

Capex Surge Positions

for Scale, but Leverage Risks Rise

’s shares have risen ~6% over the past three sessions after the board approved multiple expansion projects, an acquisition, and a strategic MoU. These initiatives strengthen the company’s long‑products portfolio, deepen raw‑material integration, and accelerate its transition toward low‑carbon steelmaking. However, the aggressive capex cycle comes at a time of weak steel margins, raising concerns about leverage and execution. The centrepiece is a 4.8 mtpa expansion at Neelachal Ispat Nigam Ltd, taking capacity from 1 mtpa to 5.8 mtpa. This sharply increases Tata Steel’s exposure to long products—a segment that forms 55–60% of India’s steel demand but only ~15% of Tata Steel’s output today. This shift aligns the company with a structurally higher‑margin, retail‑driven market. Two additional projects enhance downstream capabilities: - 2.5 mtpa thin slab caster & rolling mill at Meramandali, Odisha - 0.7 mtpa HRPGL line at Tarapur, Maharashtra The HRPGL unit will produce advanced automotive steel grades currently imported, improving domestic substitution and margin mix. The proposed 1 mtpa HIsarna plant is a breakthrough low‑carbon steelmaking process that eliminates coke and uses lower‑grade ore and slag. With ₹3,000/tonne cost savings and Tata Steel holding the patent, successful commercialisation could create a long‑term competitive moat. Tata Steel will acquire 50.01% of Thriveni Pellets for ₹636 crore, securing supply from a 4 mtpa pellet plant near Kalinganagar. The MoU with Lloyds Metals opens access to Gadchiroli iron ore, supports Lloyds’ upcoming steel plant, and explores a 6 mtpa greenfield JV—marking Tata Steel’s entry into western India. Capex of ₹45,000–50,000 crore over 3–4 years (excluding Lloyds JV) comes amid depressed margins. Net debt/EBITDA is 3x (Q2FY26) and must fall to the 2.75–3x target. Valuations at 6.5–7x FY27 EV/EBITDA are near long‑term averages, making domestic demand recovery critical for near‑term stock performance.

See More